Friday, 25 September 2026European Markets

LAVIDE HOLDING Stock Impressive Jump On Monday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with LAVIDE HOLDING (LVIDE.AS) rising 34.78% to €0.31 on Monday while AEX-Index fell 0.43% to €895.75.

LAVIDE HOLDING's last close was €0.23, 28.13% below its 52-week high of €0.32.

About LAVIDE HOLDING

Lavide Holding N.V. does not have significant operations. Previously, it was engaged in the provision of integrated information technology solutions for medium to large-sized companies and organizations. The company was formerly known as Qurius N.V. and changed its name to Lavide Holding N.V. in July 2013. Lavide Holding N.V. is based in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, LAVIDE HOLDING has a trailing twelve months EPS of €-0.02.

Yearly Top and Bottom Value

LAVIDE HOLDING's stock is valued at €0.31 at 22:34 EST, below its 52-week high of €0.32 and way higher than its 52-week low of €0.18.

Volume

Today's last reported volume for LAVIDE HOLDING is 254347 which is 4052.6% above its average volume of 6125.

Volatility

LAVIDE HOLDING's last week, last month's, and last quarter's current intraday variation average was a negative 2.59%, a negative 0.70%, and a positive 4.47%.

LAVIDE HOLDING's highest amplitude of average volatility was 2.59% (last week), 4.38% (last month), and 4.47% (last quarter).

More news about LAVIDE HOLDING (LVIDE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com